Market Overview

Cramer Recommends J&J For Best Big Pharma Pipeline Play

Share:
Related JNJ
Here's Everything You Need To Know About Blue Chip Stocks
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
Buying Dividend Growth Stocks Without Looking; 17 Months Later (Seeking Alpha)

Coming out of the Twittersphere Wednesday afternoon: a trader asks Jim Cramer about a potential big pharma play which could fit into his or her portfolio. The trader specified the play would need to be for over the next five years. Cramer responded:

J&J (NYSE: JNJ) shares do not seem to be responding to the recommendation by Cramer, but are trading at afternoon highs. The stock is down 0.6 percent to $92.74 at last check.

Posted-In: News Jim Cramer Media Trading Ideas

 

Related Articles (JNJ)

View Comments and Join the Discussion!